Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage III Pancreatic Adenocarcinoma (DIRECT)
Summary
The purpose of this registry trial is to evaluate the safety and efficacy of the NanoKnife System with standard of care treatment or standard of care treatment only in patients with stage III pancreatic cancer.
General Information
NCT#: NCT03899649
Study ID: 2019-ONC-02
Trial Phase: Phase II
Trial Sponsor: Angiodynamics, Inc.
Therapies Used in This Trial: Irreversible Electroporation (IRE), Physician's discretion on standard of care